These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 21766293)

  • 1. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
    Cooper TM; Franklin J; Gerbing RB; Alonzo TA; Hurwitz C; Raimondi SC; Hirsch B; Smith FO; Mathew P; Arceci RJ; Feusner J; Iannone R; Lavey RS; Meshinchi S; Gamis A
    Cancer; 2012 Feb; 118(3):761-9. PubMed ID: 21766293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.
    Rubnitz JE; Inaba H; Dahl G; Ribeiro RC; Bowman WP; Taub J; Pounds S; Razzouk BI; Lacayo NJ; Cao X; Meshinchi S; Degar B; Airewele G; Raimondi SC; Onciu M; Coustan-Smith E; Downing JR; Leung W; Pui CH; Campana D
    Lancet Oncol; 2010 Jun; 11(6):543-52. PubMed ID: 20451454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.
    Gamis AS; Alonzo TA; Meshinchi S; Sung L; Gerbing RB; Raimondi SC; Hirsch BA; Kahwash SB; Heerema-McKenney A; Winter L; Glick K; Davies SM; Byron P; Smith FO; Aplenc R
    J Clin Oncol; 2014 Sep; 32(27):3021-32. PubMed ID: 25092781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
    Roman E; Cooney E; Harrison L; Militano O; Wolownik K; Hawks R; Foley S; Satwani P; Unal E; Bhatia M; Bradley B; Del Toro G; George D; Garvin J; van de Ven C; Cairo MS
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7164s-7170s. PubMed ID: 16203817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients.
    Brunnberg U; Mohr M; Noppeney R; Dürk HA; Sauerland MC; Müller-Tidow C; Krug U; Koschmieder S; Kessler T; Mesters RM; Schulz C; Kosch M; Büchner T; Ehninger G; Dührsen U; Serve H; Berdel WE
    Ann Oncol; 2012 Apr; 23(4):990-6. PubMed ID: 21810729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemtuzumab ozogamicin for
    Lambert J; Pautas C; Terré C; Raffoux E; Turlure P; Caillot D; Legrand O; Thomas X; Gardin C; Gogat-Marchant K; Rubin SD; Benner RJ; Bousset P; Preudhomme C; Chevret S; Dombret H; Castaigne S
    Haematologica; 2019 Jan; 104(1):113-119. PubMed ID: 30076173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
    Kell WJ; Burnett AK; Chopra R; Yin JA; Clark RE; Rohatiner A; Culligan D; Hunter A; Prentice AG; Milligan DW
    Blood; 2003 Dec; 102(13):4277-83. PubMed ID: 12933575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.
    Burnett AK; Hills RK; Milligan D; Kjeldsen L; Kell J; Russell NH; Yin JA; Hunter A; Goldstone AH; Wheatley K
    J Clin Oncol; 2011 Feb; 29(4):369-77. PubMed ID: 21172891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
    Aplenc R; Alonzo TA; Gerbing RB; Lange BJ; Hurwitz CA; Wells RJ; Bernstein I; Buckley P; Krimmel K; Smith FO; Sievers EL; Arceci RJ;
    J Clin Oncol; 2008 May; 26(14):2390-3295. PubMed ID: 18467731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
    Hills RK; Castaigne S; Appelbaum FR; Delaunay J; Petersdorf S; Othus M; Estey EH; Dombret H; Chevret S; Ifrah N; Cahn JY; Récher C; Chilton L; Moorman AV; Burnett AK
    Lancet Oncol; 2014 Aug; 15(9):986-96. PubMed ID: 25008258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Fransecky L; Koller E; Wulf G; Schleicher J; Ringhoffer M; Greil R; Hertenstein B; Krauter J; Martens UM; Nachbaur D; Samra MA; Machherndl-Spandl S; Basara N; Leis C; Schrade A; Kapp-Schwoerer S; Cocciardi S; Bullinger L; Thol F; Heuser M; Paschka P; Gaidzik VI; Saadati M; Benner A; Schlenk RF; Döhner K; Ganser A;
    Lancet Haematol; 2023 Jul; 10(7):e495-e509. PubMed ID: 37187198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.
    O'Hear C; Inaba H; Pounds S; Shi L; Dahl G; Bowman WP; Taub JW; Pui CH; Ribeiro RC; Coustan-Smith E; Campana D; Rubnitz JE
    Cancer; 2013 Nov; 119(22):4036-43. PubMed ID: 24006085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia.
    Petersdorf SH; Kopecky KJ; Slovak M; Willman C; Nevill T; Brandwein J; Larson RA; Erba HP; Stiff PJ; Stuart RK; Walter RB; Tallman MS; Stenke L; Appelbaum FR
    Blood; 2013 Jun; 121(24):4854-60. PubMed ID: 23591789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial.
    Burnett A; Cavenagh J; Russell N; Hills R; Kell J; Jones G; Nielsen OJ; Khwaja A; Thomas I; Clark R;
    Haematologica; 2016 Jun; 101(6):724-31. PubMed ID: 26921360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.
    Ito Y; Wakita A; Takada S; Mihara M; Gotoh M; Ohyashiki K; Ohtake S; Miyawaki S; Ohnishi K; Naoe T
    Int J Hematol; 2012 Oct; 96(4):485-91. PubMed ID: 22956429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of adding gemtuzumab ozogamicin to induction chemotherapy for newly diagnosed acute myeloid leukemia: a meta-analysis of prospective randomized phase III trials.
    Li X; Xu SN; Qin DB; Tan Y; Gong Q; Chen JP
    Ann Oncol; 2014 Feb; 25(2):455-61. PubMed ID: 24478322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
    Ashaye AO; Khankhel Z; Xu Y; Fahrbach K; Mokgokong R; Orme ME; Lang K; Cappelleri JC; Mamolo C
    Future Oncol; 2019 Feb; 15(6):663-681. PubMed ID: 30450960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of gemtuzumab ozogamicin to chemotherapy in adult patients with acute myeloid leukemia.
    Kell J
    Expert Rev Anticancer Ther; 2016; 16(4):377-82. PubMed ID: 26942450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.